Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact

Phase 3positivePositive

AI Analysis

Summary

Alumis announced positive Phase III trial results for its psoriasis pill candidate. Analyst sentiment remains cautious regarding the clinical and commercial significance of the achievement.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Importance:6/10

Sentiment:

0.30

Phase_3_DataPsoriasisOral_TherapyClinical_Trial

Related Companies

$AMGN

Read the original article

Published by yahoo_finance on October 9, 2026 5:11 PM

Read Original